All Updates

All Updates

icon
Filter
Partnerships
Integrated Biosciences partners with Illumina Ventures Labs for next-generation therapeutic drug discovery
AI Drug Discovery
May 28, 2024
This week:
Funding
Lhyfe receives EUR 11 million grant from Klimatklivet for green hydrogen project in Sweden
Hydrogen Economy
Yesterday
Product updates
XRAI Glass launches AR One glasses at USD 1449 for hearing-impaired individuals
Extended Reality
Yesterday
Funding
VR therapy platform CUREosity raises EUR 3.8 million in funding to expand market presence
Extended Reality
Yesterday
Last week:
Product updates
Coinbase updates mobile wallet to add decentralized app browser
Decentralized Finance (DeFi)
Jun 22, 2024
Product updates
Coinbase updates mobile wallet to add decentralized app browser
Web3 Ecosystem
Jun 22, 2024
M&A
OpenAI acquires Rockset to power retrieval infrastructure
Data Infrastructure & Analytics
Jun 21, 2024
M&A
OpenAI acquires Rockset to power retrieval infrastructure
Foundation Models
Jun 21, 2024
Partnerships
Product updates
Anthropic releases Claude 3.5 Sonnet, the first model in the 3.5 series
Foundation Models
Jun 21, 2024
Funding
Paramount Planet Product raises USD 1 million in federal grant funding to support commercialization
Bio-based Materials
Jun 21, 2024
Regulation/policy
Apple delays launch of Apple Intelligence features in EU citing regulatory concerns
Generative AI Applications
Jun 21, 2024
AI Drug Discovery

AI Drug Discovery

May 28, 2024

Integrated Biosciences partners with Illumina Ventures Labs for next-generation therapeutic drug discovery

Partnerships

  • California-based biotechnology firm Integrated Biosciences has partnered with Illumina Ventures Labs to unite Integrated Biosciences’ drug discovery technology with Illumina's sequencing capabilities. The terms and financial details of the agreement have not been disclosed.

  • Under the collaboration, Integrated Biosciences plans to develop new kinds of small-molecule therapeutics that alter cell behavior with scientific and monetary support from Illumina. These candidates will target various diseases related to aging and development. Integrated Biosciences claims that this collaboration will help generate large-scale datasets that detail modifying cellular components such as nucleic acids to develop novel treatments.

  • Integrated Biosciences leverages synthetic biology and ML to control cellular stress responses, enabling the discovery of treatments for diseases such as cancer, diabetes, and osteoarthritis. The company’s pipeline includes several clinical-stage programs varying between modulating aging cells and cellular stress and protecting against cellular damage, among others.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.